Andrew Sharples

Partner, UK and European Patent Attorney, Solicitor
London, EIP Europe LLP

As head of the EIP Life practice group, Andrew focuses on the life sciences; his clients ranging from start-ups to major pharmaceutical and biotech companies. His technical experience covers a range of biotechnology, pharmaceuticals, and medical devices technologies. He has also conducted patent litigation in a range of technologies, and is an expert on the complexities of FRAND.

He joined EIP after a decade in the patent group of a major international law firm. His expertise includes patent drafting and prosecution, oppositions, supplementary protection certificates and life cycle strategies. A solicitor as well as a Chartered and European patent attorney, Andrew has advised on litigious proceedings from the Patents County Court to the House of Lords, and on corporate transactions including VC investment and multi-million pound acquisitions.

Andrew has a degree in Molecular Biology from the University of Edinburgh and a master's in the Management of Intellectual Property from Queen Mary’s College, University of London.


  • Representing Unwired Planet in their FRAND dispute with Huawei.
  • Advising Tate & Lyle on the intellectual property aspects of acquisitions of food technology companies.
  • Representing Amgen in a patent infringement dispute with Hospira in relation to pegfilgrastim (Case Ref: HC09C04064 Hospira, Inc. & anr v Amgen Inc.).
  • Representing Bioprogress PLC in a patent entitlement dispute (Stanelco Fibre Optics Ltd v Bioprogress Technology Ltd).
  • Representing Niche Generics in their patent infringement and validity action in relation to perindopril (Les Laboratories Servier v Niche Generics).

Recent work

  • Acting for Unwired Planet International Limited in their FRAND litigation against Google, Samsung & Huawei.
  • Prosecution of the cell therapy patent portfolio for Cytori Therapeutics.
  • Conduct of a number of “straw man” oppositions in relation to a range of small molecule and biotherapeutic technologies.
  • Development of a patent portfolio on behalf of Tate & Lyle in relation to enzymatic processing systems.
  • Providing ongoing non-infringement advice in relation to development of a new product for an FTSE 100 company.
  • Acting for Conversant Wireless Licensing in patent and FRAND litigation against Huawei & ZTE.

Published articles

  • 24 December 2016
    Journal of Intellectual Property Law & Practice 2016, Threats to infringe a patent application: no barrier to justification (link)
  • 29 September 2014
    IP Law 360, Good news for originators of antibody products (link)
  • 22 July 2014
    Intellectual Property Magazine, SPCs for medical devices: continuing disharmony (link)
  • 11 April 2014
    IP Law 360, SPCs - we wait in vain for clarity from Europe (link)
  • November 2013
    Intellectual Property Counsellor, Europe's unitary patent system: a horse designed by a committee
  • 19 September 2013
    IP Pro Life Sciences, Innovative Times (link)
  • 23 June 2013
    JIPLP, So when is a patent claim too broad? (link)
  • 10 August 2011
    Genetic Engineering and Biotechnology News, Uncertainty and disharmony plague patent term extensions in Europe (link)
  • 2 June 2011
    Genetic Engineering and Biotechnology News, Europe Awaits Decision on Patents, hESCs, and Morality (link)
  • 23 March 2011
    Genetic Engineering and Biotechnology News, Gene Patents in Europe Relatively Stable Despite Uncertainty in the US (link)


  • Biotechnology
  • Pharmaceuticals

Education and qualifications


  • 1999 — 2000
    MSc Management of Intellectual Property, Queen Mary College, University of London
  • 1994 — 1998
    BSc Molecular Biology, University of Edinburgh

Career history

  • 2010 — present
    Partner, EIP
  • 2000 — 2010
    Senior Associate, McDermott Will & Emery

Awards and recognition

  • Ranked as a "Patent Star", IP Stars 2020 (link)
  • Ranked as a "Patent Star", IP Stars 2019 (link)
  • Legal 500, 2018: Recommended Patent Attorney
  • Ranked as "Patent Star", IP stars 2018
  • Legal 500, 2017: Noted as a “patent law expert” and a "key figure" for patent prosecution and patent litigation.
  • A "star litigator" in the firm, IP Stars 2017 (link)

Speaking engagements

  • 4 May 2016
    One Nucleus BioWednesday, Does Every Tech Transfer Office Need an Investment Fund? (link)
  • 3 June 2015
    One Nucleus BioWednesday, Developing and Commercialising Cell-based Platforms (link)
  • June 2014
    One Nucleus BioWednesday, The Value of Intellectual Property (link)
  • July 2013
    One Nucleus BioWednesday, Managing IP Litigation on a Budget (link)
  • January 2013
    One Nucleus Life Sciences Leadership, Assessing freedom to operate in the antibody-drug conjugation (ADC) arena (link)
  • October 2012
    Cardiff Medicentre Breakfast Briefing, Managing Intellectual Property from Start-up to Exit (link)
  • June 2012
    EIP Elements seminar, A Mock EPO Opposition
  • June 2012
    C5, 11th International Forum of Pharma Patent Lifecycles (link)
  • November 2011
    EIP Life seminar, Patent Term Extensions and SPCs
  • June 2011
    London Business School seminar, Managing IP from start-up to exit